Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. - Wikidata - awgldk - TriplyDB

Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.

Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.

http://www.wikidata.org/entity/Q33536900

about

Corticosteroid implants for chronic non-infectious uveitis Corticosteroid implants for chronic non-infectious uveitis Updates on the Clinical Trials in Diabetic Macular Edema Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant INTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA: PHARMACOKINETIC CONSIDERATIONS Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy Diabetic macular oedema: evidence-based treatment recommendations for Asian countries.Diabetic macular edema: New promising therapies.Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy Economic considerations of macular edema therapies Diabetic macular edema: new trends in management.Diabetic macular edema: therapeutic options.Pharmacotherapy for uveitis: current management and emerging therapy.Review of therapeutic advances in diabetic retinopathy.Pathophysiology and treatment of diabetic retinopathy.Current treatments in diabetic macular oedema: systematic review and meta-analysis Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema.Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide Local therapies for inflammatory eye disease in translation: past, present and future Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant.One-Year Feasibility Study of Replenish MicroPump for Intravitreal Drug Delivery: A Pilot Study.A novel intravitreal fluocinolone acetonide implant (Iluvien(®)) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series Current intravitreal pharmacologic therapies for diabetic macular edema.Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN(®)) in Patients with Diabetic Macular Edema Elevated Intraocular Pressure After Intravitreal Steroid Injection in Diabetic Macular Edema: Monitoring and Management.Intravitreal Corticosteroids in the Management of Diabetic Macular Edema Diabetic Retinopathy Clinical Practice Guidelines: Customized for Iranian Population.Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis.Think global--act local: intravitreal drug delivery systems in chronic noninfectious uveitis.The evolving treatment options for diabetic macular edema.Novel Intraocular Therapy in Non-infectious Uveitis of the Posterior Segment of the Eye.A comprehensive review and update on the non-biologic treatment of adult noninfectious uveitis: part I.Sustained-release fluocinolone acetonide intravitreal insert for macular edema: clinical pharmacology and safety evaluation.Nonbiological pharmacotherapies for the treatment of diabetic macular edema.Fluocinolone acetonide for the treatment of diabetic macular edema.Drug, delivery and devices for diabetic retinopathy (3Ds in DR).Fluocinolone acetonide and its potential in the treatment of chronic diabetic macular edema.Evaluation of extended release brimonidine intravitreal device in normotensive rabbit eyes.Pharmacology of Corticosteroids for Diabetic Macular Edema.New Drugs and New Posterior Delivery Methods in CME.

P2860

Q24186144-ED99DC71-594F-4726-9F27-77BEA1707339 Q24198202-3079F3D4-2911-49CF-BD89-DCA20A69D79F Q26767100-220A218E-0F03-4E84-9B17-BB08B7D93BF9 Q26775853-4C0623AD-9F85-4B35-AEF8-A1CD74273345 Q26782198-7D5CF2DA-56EA-4151-A794-F2875E8FD7A2 Q28078199-F4EC9FCB-4FBC-4025-99E5-EF4B78CE4182 Q30101045-6F8B7A77-D376-461F-88A3-3A2A64596781 Q30415630-1EC6A7A4-8073-4DF6-897F-43161F10BC41 Q33705718-E71E2EA2-81B5-42E7-8CD6-252ABA7FC0A6 Q33878122-163D9173-57F6-4208-ACE1-7D445AC54C86 Q34091784-69524BD7-C9A8-4317-93BA-3DC91AFD4769 Q34185374-C7009695-1133-4DDB-9EE1-79003B2551A1 Q34274075-CA7643CB-9CE6-48C1-8FE7-2B4F1D57DC02 Q34475449-766046C7-0DA9-4FDE-B972-D4DAA216B192 Q34528134-6D094BB3-CD1F-45AA-88E9-4B458C12FA71 Q34606190-D4E1B51A-9CD2-4C44-B7E8-8410766EF819 Q34758061-9CCDBA49-4DA7-4287-9915-2B2AFB4E50F3 Q34816580-B41D0272-39C1-44AE-991F-72243B51D083 Q34892662-EEB40DE5-3D44-4743-ADD2-8E85B52B5538 Q35128723-F4DF2DD8-19AB-4E99-AC40-A22D177596C9 Q35167647-AF019959-8DB8-4985-B937-216466B40BF9 Q35592903-54945E8B-CF71-435C-930D-75633A9DF6DF Q35650268-FE1CA917-AC65-45E6-B83C-5650B2EF9481 Q35925938-54DCC429-6964-4D41-9F6A-B8791DBDEAB2 Q36013578-67E679E1-EE76-478C-8361-F9FB57E91CEE Q37287831-344F500F-A689-4A35-8D62-C5F61E1AC3A2 Q37477129-67B1A758-11A6-4DB0-8488-77EECC7F983F Q37845396-5CB9CEF1-3F24-4D4E-945C-A023C16C3EC2 Q38069093-A460D5CA-C154-4BDF-A223-D45248CCA8F7 Q38150855-BBAADA9D-D722-4F6F-8385-EB962BD8380C Q38211433-B74E0364-A48E-48AC-AD0B-8AC6185B8A4D Q38250116-43DEF8DD-3201-4E39-A1DA-69C763880C98 Q38494605-42DBEF64-EABB-4293-90AE-1D1A74603E2C Q38622256-061C1F84-452A-4365-B2A1-B72FA57F321B Q38648612-A6C52996-FE9F-4A25-A900-83A042E97BF2 Q38832441-60D18FB9-6770-4707-92A1-FE31AC7F4806 Q41236033-896B040C-50FE-4055-82B3-8469B40814C9 Q47653427-0BCA40BA-CECA-4CB4-946C-41E924A5131E Q47753853-7AEC20D4-7B79-4360-A0E9-C2F0E9E83FA8 Q50073381-0C9025B1-B8FF-48E8-BA71-F8A3797AE5A3

P2860

Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.

http://www.wikidata.org/entity/Q33536900

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.

@ast

Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.

@en

Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.

@nl

type

label

Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.

@ast

Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.

@en

Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.

@nl

prefLabel

Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.

@ast

Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.

@en

Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.

@nl

P1433

Q33536900-21DA6659-51A3-46B0-89ED-CC6D5D4F0DFE

P1476

Q33536900-6515EA4E-E5FE-4818-8B69-43DC435AF3FA

P2093

Q33536900-02F6CA6E-A520-4494-9015-14B2D394579C

Q33536900-03F4385E-53C2-48C1-9F58-E8B2230298A6

Q33536900-04E3BBC9-7E81-4D4E-9F51-2386E84AAA70

Q33536900-1F23E7C4-1AA5-4638-9A9B-C54A1ABC60FC

Q33536900-4008250E-F7ED-45E2-AD1E-D3CA511C4472

Q33536900-4A41976A-8229-40B7-9837-96C892A675EA

Q33536900-546A9C6B-941C-425D-9016-A7D0A3DCA57F

Q33536900-60467E0E-8D9B-46AF-ADD0-1D92EF9531CD

Q33536900-6A38A340-BC70-486B-B0D9-9E3F46AD3D01

Q33536900-739D13F4-D33F-4AA0-8D04-709C7D613511

P304

Q33536900-4C1AAD6E-B9C3-402B-B32B-A93AA6B7FD68

P31

Q33536900-C8A3721F-944C-4D03-B8BB-0398F8FB7E50

P356

Q33536900-C77A9398-A699-4DEE-9AB5-512D982E9405

P433

Q33536900-EDC896CE-B112-4D2B-8093-9C6ABC0B1277

P478

Q33536900-E0E7FD02-15CD-40C9-81BC-F26DF5DFA962

P50

Q33536900-6995C2E0-C70F-4327-AB32-FFD1422EC317

P577

Q33536900-4A812EFE-709D-4352-99A6-C38BCC3558E2

P698

Q33536900-5F60CAFE-8EDA-468C-AE63-1856E81BBBA1

P356

J.OPHTHA.2009.11.024

P1433

P1476

Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.

@en

P2093

Barry Kapik

http://www.w3.org/2001/XMLSchema#string

David M Brown

http://www.w3.org/2001/XMLSchema#string

Famous Study Group

http://www.w3.org/2001/XMLSchema#string

Frances Kane

http://www.w3.org/2001/XMLSchema#string

Gulnar Hafiz

http://www.w3.org/2001/XMLSchema#string

Kathleen Billman

http://www.w3.org/2001/XMLSchema#string

Ken Green

http://www.w3.org/2001/XMLSchema#string

Leonard Feiner

http://www.w3.org/2001/XMLSchema#string

Miguel Busquets

http://www.w3.org/2001/XMLSchema#string

Nelson Sabates

http://www.w3.org/2001/XMLSchema#string

P304

1393-9.e3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.OPHTHA.2009.11.024

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

Thomas A Ciulla

P577

2010-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20202684

http://www.w3.org/2001/XMLSchema#string